MARY GAMEL: Open Payments
NPI 1073884987 · THOMASTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$533 in 31 payments from 9 companies in 2025. Trend: 2023 $556 · 2024 $378 · 2025 $533
Food & beverage: $533
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $153 |
| AstraZeneca Pharmaceuticals LP | 4 | $102 |
| PFIZER INC. | 3 | $63 |
| Novartis Pharmaceuticals Corporation | 3 | $59 |
| ABBVIE INC. | 2 | $53 |
| Novo Nordisk Inc | 3 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
Products named: OTEZLA, FARXIGA, LEQVIO, VRAYLAR, ELIQUIS, Kerendia, PAXLOVID, MOUNJARO.
Industry payments across GA — which companies pay providers there.
